SCHEMBL6043761

SCHEMBL6043761

COC(=O)c1cc(OC)c2cccc(OC)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
RAB9A P51151 1/20 0.46
CDC25B P30305 2/20 0.45
FTO Q9C0B1 1/20 0.44
CYP3A4 P08684 1/20 0.44
TSHR P16473 2/20 0.44
PLK1 P53350 1/20 0.44
PFKFB3 Q16875 1/20 0.43
PFKFB4 Q16877 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC3 O15379 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6043174 0.87 FTO (0.52) MAPTGLAGAAPOLBHPGD
SCHEMBL1812029 0.85 CA12 (0.55) MAPTGAAPOLBHPGDKMT2A
SCHEMBL7789471 0.81 SMN1; SMN2 (0.48) MAPTPOLBHPGDNPSR1KMT2A
SCHEMBL4779330 0.80 GAA (0.59) MAPTGLAGAAPOLBHPGD
SCHEMBL18288014 0.80 HPGD (0.53) MAPTPOLBHPGDNPSR1KMT2A
SCHEMBL31493128 0.80 HPGD (0.53) MAPTPOLBHPGDNPSR1KMT2A
SCHEMBL27185238 0.78 SYK (0.55) MAPTPOLBKDM4EALDH1A1SMN1; SMN2
SCHEMBL7789713 0.78 FTO (0.53) MAPTGAAPOLBHPGDNPSR1
SCHEMBL672360 0.78 CDC25B (0.54) MAPTKMT2AMEN1RAB9ACDC25B
SCHEMBL4099121 0.77 PLK1 (0.56) MAPTGLAGAAHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 MAPT 43/4885GLA 16/4885GAA 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.